The Department for Health and Social Care has asked NICE to conduct an appraisal of Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma.
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early-August 2021 when we will write to you about how you can get involved.